Using Cabozantinib and Vandetanib in Medullary Thyroid Cancer
Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.
Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.
Cabozantinib and vandetinib are both approved agents and work through similar mechanisms, as tyrosine kinase inhibitors of RET. Though these drugs target RET, which is important in medullary thyroid cancer, they also target VEGFR, EGFR, and MET.
Clinical Pearls I
Cabozantinib and vandetinib both showed benefit to progression-free survival in phase III trial vs placebo. The problem with medullary thyroid cancer, Sherman says, is that it is a slow-growing disease and can be treated with many other drugs. It is unknown if either drug can demonstrate true benefit to overall survival or quality of life.
- Cabozantinib and vandetanib are both approved tyrosine kinase inhibitors of RET
- Cabozantinib and vandetanib also target VEGFR, EGFR, and MET
Clinical Pearls II
- Cabozantinib and vandetanib both showed PFS benefit in phase III trials vs placebo
- It is unknown if either drug leads to any true benefit to overall survival or quality of life
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
